Genetic correlation between Prothrombin G20210A polymorphism and retinal vein occlusion risk

Yuanyuan Zou 1,2, Xi Zhang 2, Jingyi Zhang 2, Xiangning Ji 2, Yuqing Liu 2 and Shaozhen Zhao 1

1Department of Refraction and Cornea, Tianjin Medical University Eye Hospital, School of Optometry and Ophthalmology, Tianjin Medical University, Tianjin, China
2The Second Department of Ophthalmology, Cangzhou Central Hospital, Cangzhou, China

Abstract

The aim of this study was to perform an updated meta-analysis to quantitatively investigate the association between G20210A polymorphism of Prothrombin gene and the risk of retinal vein occlusion (RVO), based on the available publications with inconsistent results. We utilized the Stata software to perform the heterogeneity test, association test, Begg’s and Egger’s tests, and sensitivity analysis. We searched three on-line databases (PubMed, Embase, and WOS) and obtained a total of 422 articles. Based on our selection criteria, 24 case-control studies were finally enrolled in this overall meta-analysis; a subgroup analysis by the factors ethnicity, control source, and RVO type was done. Through the association test of overall meta-analysis, we did not observe a significant difference between RVO cases and controls under the A vs G (allele) (z=1.49, P=0.137), A vs G (carrier) (z=1.42, P =0.155), GA vs GG (z=1.50, P=0.135), and GA+AA vs GG (z=1.50, P=0.135). Furthermore, we observed similar negative results in the association test of subgroup analysis (all P >0.05). Heterogeneity, Begg’s, and Egger’s tests excluded the presence of high heterogeneity and publication bias. Statistically stable results were observed in the sensitivity analyses. Based on integrated analysis of the current evidence, Prothrombin gene G20210A polymorphism is likely unrelated to the risk of RVO.

Key words: Prothrombin; Retinal vein occlusion; Polymorphism; Risk; Meta-analysis

Introduction

Retinal vein occlusion (RVO) is a common retinal vascular disease, and often contributes to the occurrence of visual decline or loss, especially for middle-aged or elderly individuals (1). The main clinical characteristics of RVO include retinal vein dilatation, retinal and subretinal hemorrhages, macular edema, or retinal ischemia (1). Central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) are two main types of RVO (1,2). The exact pathogenesis of RVO remains unclear. Genetic variants within a series of genes were reportedly associated with the risk of RVO (3).

Factor V G1691A (Factor V Leiden or R506Q) and G20210A polymorphism (rs1799963) within Prothrombin (Factor II) gene are the most common inherited thrombophilic mutations (4). Previously, we conducted an updated meta-analysis and reported that “GA” genotype of Factor V G1691A polymorphism is associated with an increased susceptibility to RVO (particularly CRVO) in a Caucasian population (2). Herein, we investigated the role of Prothrombin G20210A polymorphism in the risk of RVO. Prothrombin G20210A polymorphism may lead to the alteration of a single base from guanine (G) to adenine (A) at “20210” site in the 3’-untranslated region, and the impaired enzyme activity of prothrombin protein.

To the best of our knowledge, only two meta-analyses on the genetic role of Prothrombin G20210A in the susceptibility to RVO were reported in 2005 (5) and 2013 (6). In the present study, a total of 24 eligible case-control studies were enrolled for our updated meta-analysis, which followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) (2).
electronically searched. No restrictions of publication period or language were utilized. Detailed search terms are shown in Supplementary Table S1.

**Selection strategy**

Three authors (Y. Zou, X. Ji, and Y. Liu) selected the eligible case-control studies. Based on the principles of PICOS (population, intervention, comparator, outcomes and study designs), the specific inclusion criteria were utilized: (P) cases of RVO; (I) Prothrombin G20210A polymorphism; (C) healthy individuals or negative controls; the genotype frequency distribution should follow Hardy-Weinberg equilibrium (HWE); (O) “GG”, “GA”, and “AA” genotype frequency data of G20210A polymorphism in both cases and controls; (S) case-control studies. Articles were removed according to our specific exclusion criteria, which were duplicate studies, other disease or gene, cell or animal data, review or meta-analysis, meeting abstract, case report or trial, and lack of confirmed genotype data. When encountering disagreements, a discussion with another author (S. Zhao) took place for a final consensus.

**Data extraction**

Three authors (Y. Zou, X. Ji, and Y. Liu) extracted the data from the eligible case-control studies. A form was utilized to summarize the characteristics, including the first author, publication year, country, ethnicity, genotype frequency, control source, genotyping assay, and sample size. When genotype frequency data was missing or

---

**Figure 1.** Flow diagram for identifying eligible case-control studies.

Braz J Med Biol Res | doi: 10.1590/1414-431X20198217
unavailable, we tried to contact the author through an e-mail.

Statistical analysis

Overall meta-analysis and subgroup analyses by three factors, including ethnicity, control source, and RVO type, were performed using Stata software (version 12.0, Stata Corporation, USA). In the heterogeneity test, a P value of Cochran’s Q statistic larger than 0.1 or \( I^2 \) value less than 50% indicated the existence of heterogeneity between studies, and a fixed-effect model was used in the association test (Mantel-Haenszel statistics). Four inheritance models, including A vs G (allele), A vs G (carrier), GA vs GG (heterozygote), and GA + AA vs GG (dominant), were utilized. The odds ratios (OR), 95% confidence intervals (CI), and P values of association tests were determined.

Begg’s and Egger’s tests were performed to assess the potential publication bias. P values less than 0.05 indicated the existence of potential publication bias.

Table 1. Heterogeneity test and publication bias analysis.

| Genetic models        | Heterogeneity test | Model | Begg’s test | Egger’s test |
|-----------------------|--------------------|-------|-------------|--------------|
|                       | N  | \( I^2 \) | chi\(^2\) | P  | z     | P   | t  | P   |
| A vs G (allele)       | 24 | 0.0%  | 15.43 | 0.878 | Fixed | 1.17 | 0.244 | -0.65 | 0.520 |
| A vs G (carrier)      | 24 | 0.0%  | 14.42 | 0.914 | Fixed | 1.22 | 0.224 | -0.68 | 0.504 |
| GA vs GG              | 24 | 0.0%  | 15.93 | 0.858 | Fixed | 1.22 | 0.224 | -0.66 | 0.515 |
| GA + AA vs GG         | 24 | 0.0%  | 15.93 | 0.858 | Fixed | 1.22 | 0.224 | -0.66 | 0.515 |

N: number of studies.

Table 2. Pooled analysis of the association between Prothrombin G20210A polymorphism and RVO risk.

| Genetic model        | Group    | N  | Association test | Sample size |
|----------------------|----------|----|------------------|-------------|
|                      |          |    | OR (95%CI)       |             |
| A vs G (allele)      | Overall  | 24 | 1.28 (0.92 ~ 1.77) | 2,010 / 2,803 |
|                      | Caucasian| 22 | 1.17 (0.83 ~ 1.67) | 1,820 / 2,598 |
|                      | PB       | 18 | 1.44 (0.99 ~ 2.11) | 1,214 / 2,053 |
|                      | HB       | 5  | 0.74 (0.34 ~ 1.63) | 562 / 570 |
|                      | CRVO     | 8  | 1.40 (0.76 ~ 2.58) | 549 / 980 |
|                      | BRVO     | 6  | 1.05 (0.53 ~ 2.07) | 551 / 772 |
| A vs G (carrier)     | Overall  | 24 | 1.27 (0.91 ~ 1.76) | 2,010 / 2,803 |
|                      | Caucasian| 22 | 1.17 (0.82 ~ 1.67) | 1,820 / 2,598 |
|                      | PB       | 18 | 1.43 (0.97 ~ 2.10) | 1,214 / 2,053 |
|                      | HB       | 5  | 0.75 (0.34 ~ 1.64) | 562 / 570 |
|                      | CRVO     | 8  | 1.38 (0.75 ~ 2.56) | 549 / 980 |
|                      | BRVO     | 6  | 1.05 (0.53 ~ 2.08) | 551 / 772 |
| GA vs GG             | Overall  | 24 | 1.28 (0.93 ~ 1.78) | 2,010 / 2,803 |
|                      | Caucasian| 22 | 1.18 (0.82 ~ 1.68) | 1,820 / 2,598 |
|                      | PB       | 18 | 1.45 (0.99 ~ 2.13) | 1,214 / 2,053 |
|                      | HB       | 5  | 0.74 (0.34 ~ 1.63) | 562 / 570 |
|                      | CRVO     | 8  | 1.40 (0.76 ~ 2.60) | 549 / 980 |
|                      | BRVO     | 6  | 1.05 (0.53 ~ 2.08) | 551 / 772 |
| GA + AA vs GG        | Overall  | 24 | 1.28 (0.93 ~ 1.78) | 2,010 / 2,803 |
|                      | Caucasian| 22 | 1.18 (0.82 ~ 1.68) | 1,820 / 2,598 |
|                      | PB       | 18 | 1.45 (0.99 ~ 2.13) | 1,214 / 2,053 |
|                      | HB       | 5  | 0.74 (0.34 ~ 1.63) | 562 / 570 |
|                      | CRVO     | 8  | 1.40 (0.76 ~ 2.60) | 549 / 980 |
|                      | BRVO     | 6  | 1.05 (0.53 ~ 2.08) | 551 / 772 |

CRVO: central retinal vein occlusion; BRVO: branch retinal vein occlusion; PB: population-based control; N: number of studies; OR: odds ratio; CI: confidence interval.
In addition, sensitivity analysis was performed to evaluate the stability of statistical results.

**Results**

**Eligible case-control study selection**

After the database search, we identified a total of 422 articles [PubMed (n=120), Embase (n=147), and WOS (n=155)] and removed the 100 duplicate articles. Then, we excluded another 292 improper articles, according to our exclusion criteria [other disease or gene (n=122), containing cell or animal data (n=18), review or meta-analysis (n=60), meeting abstract, case, or trial (n=92)]. Of the remaining 30 articles, six articles were excluded because no confirmed genotype data in both case and control groups were obtained. As a result, a total of 24 eligible case-control studies (3,6–28) were enrolled. Figure 1 shows the process for the selection of eligible studies, and Supplementary Table S2 summarizes the characteristics of case-control studies.

**Meta-analysis data**

There were a total of 24 case-control studies in the overall meta-analysis. The absence of heterogeneity (P value of the heterogeneity test > 0.1, $I^2 = 0.0\%$, Table 1) led to the application of Mantel-Haenszel statistics for the association test under the fixed-effect models. As shown in Table 2, we did not observe any statistical difference for the risk of RVO between cases and controls, under the inheritance models of A vs G (allele) ($z=1.49$, $P=0.137$), A vs G (carrier) ($z=1.42$, $P=0.155$), GA vs GG ($z=1.50$, $P=0.135$), and GA + AA vs GG ($z=1.50$, $P=0.135$). Figure 2 shows the forest plot data of overall meta-analysis under the A vs G (allele) model.

**Subgroup analysis data**

Next, we performed the subgroup analyses by the factors of ethnicity (Caucasian), control source (population-based control; hospital-based control), and RVO type (BRVO or CRVO). As shown in Table 2, similar negative results were detected in the association test (all $P > 0.05$).

---

**Figure 2.** Overall meta-analysis under the A vs G (allele) model. OR: odds ratio; CI: confidence interval; N: study number.
Figure 3 shows the forest plot data in subgroup analysis by RVO type under the A vs G (allele) model. These findings suggested that G20210A polymorphism within Prothrombin gene had no role influencing the risk of central or branch retinal vein occlusion in the Caucasian population.

**Publication bias and sensitivity analysis**

We did not observe a significant publication bias in the above analyses, as P values in Begg’s test and Egger’s test were larger than 0.05 (Table 1). Figure 4A shows the Begg’s publication bias plot under the A vs G (allele) model. Additionally, we observed a relatively stable conclusion through the sensitivity analysis (Figure 4B) for the allele model; data for other models are not shown.

**Discussion**

Up to now, inconsistent conclusions on the association between Prothrombin G20210A polymorphism and RVO risk were reported. For instance, in Tunisia, Prothrombin G20210A polymorphism was reportedly linked to the risk of CRVO (P=0.007), rather than BRVO (P=0.09) (25). However, in Turkey, this polymorphism was reported not to be a risk factor of both CRVO and BRVO (19).

One case-control study in Greece also reported a non-significant association between the polymorphism within Prothrombin gene and RVO susceptibility (6). Hence, it was meaningful to undertake the relevant meta-analysis for a comprehensive evaluation.

In 2005, Janssen et al. included six case-control studies (11,23,24,27,29,30) to perform the first meta-analysis, and provided the overall OR value of 1.6 and 95%CI of 0.8–3.2, but without the P value of association test (5). In 2013, Yioti et al. (6) conducted another meta-analysis with twenty studies (7–14,16–19,23,24,27,28,30–33) and reported a negative association between Prothrombin G20210A polymorphism and RVO susceptibility.

In order to enroll the maximum number of eligible case-control studies, we systematically searched the three on-line databases (PubMed, Embase, WOS) and applied a strict selection criteria. In comparison with the two prior reports, we ruled out one case-control study without Prothrombin G20210A mutation (32) and three studies without the confirmed genotype frequency data (30,31,33) in our updated quantitative meta-analysis. Moreover, a total of eight new case-control studies (3,6,15,20–22,25,26) were added. We conducted the overall meta-analysis and stratified analysis by three factors (ethnicity, control source, and RVO type), under the allele,
Figure 4. Publication bias plot of Begg’s test (A) and sensitivity analysis data (B) under the A vs G (allele) model. See Figure 2 for reference numbers of articles cited. OR: odds ratio; CI: confidence interval.
carrier, heterozygote, and dominant models. Because the “AA” genotype frequency equaled to zero in each case-control study, we could not perform the meta-analysis under the homozygote (AA vs GG) and recessive (AA vs GG + GA) models. The same data was obtained in the heterozygote and dominant models. Although we utilized a new selection strategy and added some newly published case-control studies, no significant association between Prothrombin G20210A polymorphism and RVO risk was obtained in our updated pooling analysis.

Our sensitivity analyses indicated the statistical robustness of pooling results while the heterogeneity Begg’s and Egger’s tests data supported the absence of high heterogeneity or publication bias. In spite of this, we should consider the existence of limitations within our meta-analysis. First, just like other meta-analyses, the statistical power of our pooling analysis was affected by the small number of enrolled studies. For instance, only one case-control study was enrolled in the Asian subgroup analysis (27). The negative association between Prothrombin G20210A polymorphism and the risk of RVO was mainly detected in Caucasian populations. More case-control studies in Asian and African populations are needed. Second, few publication regions, languages, or unpublished data may lead to the presence of selection bias. Third, due to the requirement of adequate genotype data, we only analyzed the genetic effect of one polymorphism within Prothrombin gene in our meta-analysis. We cannot exclude the potential role of other Prothrombin polymorphisms. Fourth, the joint effect of Prothrombin G20210A and other genetic polymorphisms, such as 4G/5G polymorphism of Plasminogen activator inhibitor-1 (PAI-1) gene and C677T (rs1801133) polymorphism of 5,10-methylene tetrahydrofolate reductase (MTHFR) gene, in the risk of RVO needs to be evaluated.

Prothrombin G20210A polymorphism was associated with enhanced susceptibility to venous thromboembolism (VTE), especially deep venous thrombosis and pulmonary embolism (34–36). Moreover, the positive association between Prothrombin G20210A polymorphism and the risk of VTE patients after arthroplasty surgery was observed in the Caucasian population, but not the Asian population (37). In addition, Prothrombin G20210A polymorphism was found to be a potential genetic marker for myocardial infarction of a Caucasian population in an age-related manner (38). However, our updated meta-analysis data did not support the association between Prothrombin G20210A polymorphism and the risk of RVO. It is well known that RVO is a type of complicated retinal vascular disease with multifactorial etiopathogenesis (1,39,40). The specific CRVO and BRVO types exhibit different risk factors, clinical features, and treatment methods (1,39,40). A series of factors, such as age, smoking, genetic variants, ethnic population, hypertension, diabetes, and hyperhomocysteinemia may be linked to the occurrence and development of RVO.

Taken together, our updated meta-analysis did not statistically support the genetic correlation between Prothrombin gene G20210A polymorphism and the risk of central or branch retinal vein occlusion. However, additional case-control studies in different populations are still needed.

Supplementary material

Click here to view [pdf].

References

1. Jonas JB, Mones J, Glacet-Bernard A, Coscas G. Retinal Vein Occlusions. Dev Ophthalmol 2017; 58: 139–167, doi: 10.1159/issn.0250-3751.
2. Zou Y, Zhang X, Zhang J, Ji X, Liu Y. Factor V G1691A is associated with an increased risk of retinal vein occlusion: a meta-analysis. Oncotarget 2017; 8: 75467–75477, doi: 10.18632/oncotarget.20636.
3. Giannaki K, Politou M, Rouvas A, Merkouri E, Travlou A, Theodosiadis P, et al. Retinal vein occlusion: genetic predisposition and systemic risk factors. Blood Coagul Fibrinolysis 2013; 24: 279–283, doi: 10.1097/MBC.0b013e32835bfda1.
4. Andreassi MG, Botto N, Maffei S. Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening. Clin Chem Lab Med 2006; 44: 514–521, doi: 10.1515/CCLM.2006.103.
5. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93: 1021–1026, doi: 10.1160/TH04-11-0768.
6. Yioli GG, Panagiotou OA, Vartholomatos GA, Kolaitis NI, Pappa CN, Evangelou E, et al. Genetic polymorphisms associated with retinal vein occlusion: a Greek case-control study and meta-analysis. Ophthalmic Genet 2013; 34: 130–139, doi: 10.3109/13816810.2012.746376.
7. Adamczuk YP, Iglesias Varela ML, Martinuzzo ME, Cerrato GS, Forastiero RR. Central retinal vein occlusion and thrombophilia risk factors. Blood Coagul Fibrinolysis 2002; 13: 623–626, doi: 10.1097/00001721-200210000-00007.
8. Arsene S, Delahousse B, Regina S, Le Lez ML, Pisella PJ, Gruel Y. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost 2005; 94: 101–106, doi: 10.1160/TH04-10-0659.
9. Biancardi AL, Gadelha T, Borges WI, Vieira de Moraes H Jr, Spector N. Thrombophilic mutations and risk of retinal vein occlusion. Arq Bras Oftalmol 2007; 70: 971–974, doi: 10.1590/S0004-27492007000600016.
10. Boyd S, Owens D, Gin T, Bunce K, Sherafati H, Perry D, et al. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms,
factor VIII, and VWF in central retinal vein occlusion. *Br J Ophthalmol* 2001; 85: 1313–1315, doi: 10.1136/bjo.85.11.1313.

11. Cruciani F, Moramarco A, Curto T, Labate A, Recupero V, Conti L, et al. MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion. *Clin Ter* 2003; 154: 299–303.

12. Delahousse B, Arsene S, Piquemal R, Iochmann S, Le Lez ML, Poulard C, et al. The 20210A allele of the prothrombin gene is not a risk factor for retinal vein occlusion. *Blood Coagul Fibrinolysis* 1998; 9: 447–448, doi: 10.1097/00001721-199807000-00009.

13. Di Capua M, Coppola A, Albisinni R, Guida A, Di Minno MN, et al. Cardiovascular risk factors and outcome in patients with retinal vein occlusion. *J Thromb Thrombolysis* 2010; 30: 16–22, doi: 10.1007/s11239-009-0388-1.

14. Dodson PM, Haynes J, Starczynski J, Farmer J, Shigdar S, Fegan G, et al. The platelet glycoprotein IIa/IIIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion. *Eye* 2003; 17: 772–777, doi: 10.1038/sj.eye.6700452.

15. Glueck CJ, Bell H, Vadlamani L, Gupta A, Fontaine RN, Wang P, et al. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. *Arch Ophthalmol* 1999; 117: 43–49, doi: 10.1001/archopht.117.1.43.

16. Gori AM, Marucci R, Fatini C, Gensini F, Sticchi E, Sodi A, et al. Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. *Thromb Haemost* 2004; 92: 54–60, doi: 10.1160/TH03-08-0509.

17. Gumus K, Kadayifcilar S, Eldem B, Saracakisi O, Ozcebe O, Dundar S, et al. Is elevated level of soluble endothelial protein C receptor a new risk factor for retinal vein occlusion? *Clin Exp Ophthalmol* 2006; 34: 305–311, doi: 10.1111/j.1442-9071.2006.01212.x.

18. Incorvaia C, Parmegiani F, Costagliola C, Lambert G, Ferraresi P, Bernardi F, et al. The heterozygous 20210 G/A genotype prevalence in patients affected by central and branch retinal vein occlusion: a pilot study. *Graefes Arch Clin Exp Ophthalmol* 2001; 239: 251–256, doi: 10.1007/s004170010266.

19. Kalayci D, Gurgey A, Guven D, Partak H, Hasirli H. Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion. *Acta Ophthalmol Scand* 1999; 77: 622–624, doi: 10.1034/j.1600-0420.1999.770602.x.

20. Karska-Basta I, Kubicka-Trzaska A, Romanowska-Dixon B, Undas A. [Thrombophilia - a risk factor of retinal vein occlusion?]. *Klin Oczna* 2013; 115: 29–33.

21. Koylu MT, Kucukcevcilloglu M, Erdurman FC, Durukan AH, Sobaci G, Torun D, et al. Association of retinal vein occlusion, homocysteine, and the thrombophilic mutations in a Turkish population: A case-control study. *Ophthalmic Genet* 2017; 38: 352–356, doi: 10.1080/13816810.2016.1235716.

22. Kuhl-Hattenbach C, Hellstern P, Nagler DK, Kohnen T, Hattenbach LO. Prothrombin polymorphism A1991G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion. *Ophthalmic Genet* 2017; 38: 413–417, doi: 10.1080/13816810.2016.1244694.

23. Larsson J, Hillarp A. The prothrombin gene G20210A mutation and the platelet glycoprotein IIa/IIIa polymorphism PI2A in patients with central retinal vein occlusion. *Thromb Res* 1999; 96: 323–327, doi: 10.1016/S0049-3848(99)00111-5.

24. Marucci R, Bertini L, Giusti B, Brunelli T, Fedi S, Cellai AP, Poli D, Pepe G, Abbate R, Prisco D. Thrombophilic risk factors in patients with central retinal vein occlusion. *Thromb Haemost* 2001; 86: 772–776, doi: 10.1055/s-0037-1616130.

25. Mird M, Feikih-Missa N, Wathek C, Rennan R, Gabai S, Gritti N. Thrombophilic risk factors in different types of retinal vein occlusion in Tunisian patients. *J Stroke Cerebrovasc Dis* 2014; 23: 1592–1598, doi: 10.1016/j.jstrokecerebrovasdis.2013.12.048.

26. Risse F, Frank RD, Weinberger AW. Thrombophilia in patients with retinal vein occlusion: a retrospective analysis. *Ophthalmologica* 2014; 232: 46–52, doi: 10.1159/000360013.

27. Salomon O, Moisseiev J, Rosenberg N, Vidne O, Yassur I, Zivelin A, et al. Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion. *Blood Coagul Fibrinolysis* 1998; 9: 617–622, doi: 10.1097/00001721-199810000-00008.

28. Weger M, Renner W, Steinbrugger I, Cichocki L, Temmel W, Stanger O, et al. Role of thrombophilic gene polymorphisms in branch retinal vein occlusion. *Ophthalmology* 2005; 112: 1910–1915, doi: 10.1016/j.ophtha.2005.05.019.

29. Bombeli T, Basic A. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. *Am J Hematol* 2002; 70: 126–132, doi: 10.1002/ajh.10103.

30. Marucci R, Giusti B, Betti I, Evangelisti L, Fedi S, Sodi A, et al. Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. *Thromb Res* 2003; 110: 7–12, doi: 10.1016/S0049-3848(03)00293-7.

31. Albisinni R, Coppola A, Loffredo M, Cerbone AM, Di Minno G, Greco GM. Retinal vein occlusion and inherited conditions predisposing to thrombophilia. *Thromb Haemost* 1998; 80: 702–703.

32. Aras S, Yilmaz G, Alpar Is, Baltaci V, Tayanc E, Aydin P. Retinal vein occlusion and factor V Leiden and prothrombin 20210 G:A mutations. *Eur J Ophthalmol* 2001; 11: 351–355, doi: 10.1177/11206721010110406.

33. Margaglione M, Brancaccio V, Ciampa A, Papa ML, Grandone E, Di Minno G. Inherited thrombophilic risk factors in a large cohort of individuals referred to Italian thrombophilia centers: distinct roles in different clinical settings. *Haematologica* 2001; 86: 634–639.

34. Felton D, Foley EM, Traub SJ, Vodonos A, Ganetsky M. Risk of venous thromboembolism after receiving prothrombin complex concentrate for warfarin-associated intracranial hemorrhage. *J Emerg Med* 2016; 50: 1–6, doi: 10.1016/j.jemermed.2015.07.001.

35. Pomero F, Ageno W, Serraino C, Borretta V, Gianni M, Fenoglio L, et al. The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature. *Thromb Res* 2014; 134: 84–89, doi: 10.1016/j.thromres.2014.04.012.
36. Franchini M, Martinelli I, Mannucci PM. Uncertain thrombophilia markers. *Thromb Haemost* 2016; 115: 25–30, doi: 10.1160/TH15-06-0478.

37. Zhou X, Qian W, Li J, Zhang P, Yang Z, Chen W, et al. Who are at risk for thromboembolism after arthroplasty? A systematic review and meta-analysis. *Thromb Res* 2013; 132: 531–536, doi: 10.1016/j.thromres.2013.09.005.

38. Li C, Ren H, Chen H, Song J, Li S, Lee C, et al. Prothrombin G20210A (rs1799963) polymorphism increases myocardial infarction risk in an age-related manner: A systematic review and meta-analysis. *Sci Rep* 2017; 7: 13550, doi: 10.1038/s41598-017-13623-6.

39. Sawada O, Ohji M. Retinal Vein Occlusion. *Dev Ophthalmol* 2016; 55: 147–153, doi: 10.1159/issn.0250-3751.

40. Lattanzio R, Torres Gimeno A, Battaglia Parodi M, Bandello F. Retinal vein occlusion: current treatment. *Ophthalmologica* 2011; 225: 135–143, doi: 10.1159/000314718.